15 Days Price Change
Closing In
WEBSITE Inc. Year: 2017 Industry: Pharmaceuticals & Drugs Listed Page
Buy unlisted shares early and participate in the growth before public listing.
Face Value 10 per share
Price 128 to 135 per share
P/E (x) 19.6
Sales( Cr.) 98
PAT( Cr.) 5
EPS 6.9
Draft Prospectus --
Exchange BSE-SME
Company Promoters
Pre Issue Share Holding 64.03%
Post Issue Share Holding 51.38%
Listing Price: 137.45
Listing Gain: 1.78%
Current Price: 229
Gain On Issue: 229 | 0%
GMP: --
GMP %: -- %
| Application | Lots | Shares | Amount |
|---|---|---|---|
| Retail (Min) | 1 | 1000 | 135,000 |
| Retail (Max) | 1 | 1000 | 135,000 |
| S-HNI (Min) | 2 | 2000 | 270,000 |
| S-HNI (Max) | 7 | 7000 | 945,000 |
| B-HNI (Min) | 8 | 8000 | 1,080,000 |
1. Funding of expenses proposed to be incurred towards registration in Bolivia, South America 2. Purchase and installation of plant and machineries for ointment production for the purpose of export in accordance with the international standards and protocols, on the 2nd floor of the Existing Premises 3. Advertising, marketing and brand building 4. Investment in procuring hardware and software 5. Funding of working capital requirements 6. General corporate purposes
| Category | Nos | Bid | Bid (x) |
|---|---|---|---|
| QIB | 1395000 | 976500 | 0.7x |
| NII | 418500 | 2343600 | 5.6x |
| Retail | 976500 | 1650285 | 1.7x |
| EMP | 0 | 0 | 0x |
| Total | 2790000 | 4994100 | 1.8x |
| # | 1 Year | 3 Year | 5 Year | 10 Year |
|---|---|---|---|---|
| Sales CAGR | 23% | 48% | 0% | 0% |
| Operating Profit CAGR | 25% | 36% | 0% | 0% |
| PAT CAGR | 25% | 0% | 0% | 0% |
| # | 1 Year | 3 Year | 5 Year | 10 Year |
|---|---|---|---|---|
| Share Price CAGR | NA% | NA% | NA% | NA% |
| ROE Average | 35% | 28% | 22% | 22% |
| ROCE Average | 17% | 14% | 12% | 12% |
Astonea Labs Ltd.
Sco 186-187, 2nd Floor Cabin No. 206, Sector 8 C Sector 8
Astonea Labs Ltd.
Oneview Corporate Advisors Private limited
Astonea Labs Ltd.
When you leave without vesting, generally unvested ESOPs are cancelled. Vested ESOPs usually can be exercised after you depart, often within 3 to 6 months, depending on the company's ESOP plan.
For companies listed on a stock exchange, you can sell the shares any time after you exercise the ESOP option and the shares are in your demat account. If the company is unlisted or otherwise a startup, you can only sell the shares if and when the company announces a buyback or has a process for secondary sales.
Whenever you exercised your options to hold shares, you entered into a market risk situation, and if the valuation of the company drops, so do the shares.
Yes. ESOPs are valuable to the employer in that the employer is able to retain the best talent, align employee interests with company goals, and preserve cash while rewarding performance.
Open your account today and gain instant access to top unlisted shares and pre-IPO opportunities.
ChatGPT
Claude
Perplexity
